Entrada Therapeutics gets UK authorization to start Phase 1 trial of ENTR-601-44 for Duchenne

Entrada Therapeutics, Inc.

UK MHRA and REC authorized Phase 1 CTIMP for ENTR-601-44 in healthy volunteers for exon 44 skipping Duchenne.
Phase 1 will enroll ~40 participants; primary endpoint safety, plus tolerability, PK, and exon skipping in muscle.
First participant expected to be dosed September 2023; data anticipated in second half of 2024.
Cash runway extended through end of 2025, supporting Duchenne franchise and broader intracellular therapeutics.
ENTR-601-44 is lead Duchenne product candidate for patients amenable to exon 44 skipping.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.